The collection of information
described in the guidance is intended to provide background
information in support of consistent procedures to promote
well-managed meetings between OOPD and stakeholders. In some cases,
these meetings may represent a critical point in the orphan product
development process and may even have an impact on the eventual
availability of products for patients with rare diseases and
conditions. It is therefore important that these meetings be
scheduled within a reasonable time, conducted effectively, and
documented where appropriate. The draft guidance describes three
collections of information: (1) The submission of a meeting request
(for informal and formal meeting), (2) the submission of a meeting
package (for formal meetings), and (3) the submission of draft
meeting minutes (for formal and certain informal
meetings.)
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.